Nina C Botto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4985297/publications.pdf

Version: 2024-02-01

1170033 1051228 20 274 9 16 citations h-index g-index papers 20 20 20 245 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Update on Contact Sensitization in the Older Adult Population. Dermatitis, 2022, 33, 122-128.	0.8	6
2	Characterization of Residual Facial Dermatitis during Dupilumab Therapy: A Retrospective Chart Review to Delineate the Potential Role of Expanded Series Patch Testing. Dermatitis, 2022, 33, 51-61.	0.8	6
3	Allergens and marketing claims in commercial hand sanitizers: A cross-sectional study. Journal of the American Academy of Dermatology, 2022, 87, 870-872.	0.6	1
4	Racial disparities in access to patch testing: a cross-sectional study. British Journal of Dermatology, 2022, 187, 784-785.	1.4	1
5	Life after patch testing: Allergic contact dermatitis caused by propylene glycol in Vivelle transdermal estradiol patch. JAAD Case Reports, 2021, 9, 34-35.	0.4	2
6	Bridging racial differences in the clinical encounter: How implicit bias and stereotype threat contribute to health care disparities in the dermatology clinic. International Journal of Women's Dermatology, 2021, 7, 139-144.	1.1	14
7	Contact dermatitis. Nature Reviews Disease Primers, 2021, 7, 38.	18.1	47
8	The use of social media platforms to discuss and educate the public on allergic contact dermatitis. Contact Dermatitis, 2021, , .	0.8	2
9	The impact of dupilumab on patch testing and the prevalence of comorbid allergic contact dermatitis in recalcitrant atopic dermatitis: A retrospective chart review. Journal of the American Academy of Dermatology, 2020, 82, 132-138.	0.6	54
10	Pediatric contact allergens in the neonatal intensive care unit. Journal of Perinatology, 2020, 40, 1554-1559.	0.9	0
11	Validating Responsiveness of a Quality-of-Life Instrument for Allergic Contact Dermatitis. Dermatitis, 2020, 31, 209-214.	0.8	8
12	Wide dye reactors. JAAD Case Reports, 2019, 5, 877-879.	0.4	3
13	Investigating the role of allergic contact dermatitis in residual ocular surface disease on dupilumab (ROSDD),,. International Journal of Women's Dermatology, 2019, 5, 308-313.	1.1	15
14	Validating a Quality-of-Life Instrument for Allergic Contact Dermatitis. Dermatitis, 2019, 30, 300-305.	0.8	10
15	A Simulation-Based Workshop to Improve Dermatologists' Communication Skills: A Pilot for Continuing Medical Education. Dermatology and Therapy, 2019, 9, 179-184.	1.4	5
16	Patch Testing and Allergen-Specific Inhibition in a Patient Taking Dupilumab. JAMA Dermatology, 2019, 155, 120.	2.0	10
17	The Medical Necessity of Comprehensive Patch Testing. Dermatitis, 2018, 29, 107-111.	0.8	19
18	Patient Reported Improvement After Patch Testing and Allergen Avoidance Counseling: A Retrospective Analysis. Dermatology and Therapy, 2018, 8, 435-440.	1.4	5

Nina C Botto

#	Article	IF	CITATIONS
19	A review of the impact of patch testing on quality of life in allergic contact dermatitis. Journal of the American Academy of Dermatology, 2017, 76, 1000-1004.	0.6	17
20	Pediatric Contact Dermatitis Registry Inaugural Case Data. Dermatitis, 2016, 27, 293-302.	0.8	49